A clinical algorithm to determine target blood pressure in the elderly: evidence and limitations from a clinical perspective
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
As the elderly population is growing rapidly, management of hypertension in South Korea faces major challenges because the proportion of elderly hypertension patients is also increasing. The characteristics of this population are also much more complex than younger patients. Elderly hypertension is characterized by wide variations in (1) fitness or biological age, (2) white-coat effect, (3) poor functional status or frailty, (4) dependency in activities of daily living or institutionalization, (5) orthostatic hypotension, and (6) multiple comorbidities. All of these should be considered when choosing optimal target blood pressure in individual patients. Recent randomized clinical trials have shown that the benefits of intensive blood pressure control for elderly patients is greater than previously thought. For generalization of these results and implementation of the guidelines based on these studies, defining the clinician's role for individualization is critically important. For individualized decisions for target blood pressure (BP) in the elderly with hypertension, four components should first be checked. These consist of (1) the minimum requirement of functional status and capability of activities of daily living, (2) lack of harmful evidence by the target BP, (3) absence of white-coat hypertension, and (4) standing systolic BP ≥ 110 mmHg without orthostatic symptoms. Risk of decreased organ perfusion by arterial stenosis should be screened before starting intensive BP control. When the target BP differs among comorbidities, the lowest target BP should be given preference. After starting intensive BP lowering therapy, tolerability should be monitored, and the titration should be based on the mean level of blood pressure by office supplemented by out-of-office BPs. Applications of the clinical algorithms will be useful to achieve more standardized and simplified applications of target BP in the elderly.
Abstract
As the elderly population is growing rapidly, management of hypertension in South Korea faces major challenges because the proportion of elderly hypertension patients is also increasing. The characteristics of this population are also much more complex than younger patients. Elderly hypertension is characterized by wide variations in (1) fitness or biological age, (2) white-coat effect, (3) poor functional status or frailty, (4) dependency in activities of daily living or institutionalization, (5) orthostatic hypotension, and (6) multiple comorbidities. All of these should be considered when choosing optimal target blood pressure in individual patients. Recent randomized clinical trials have shown that the benefits of intensive blood pressure control for elderly patients is greater than previously thought. For generalization of these results and implementation of the guidelines based on these studies, defining the clinician's role for individualization is critically important. For individualized decisions for target blood pressure (BP) in the elderly with hypertension, four components should first be checked. These consist of (1) the minimum requirement of functional status and capability of activities of daily living, (2) lack of harmful evidence by the target BP, (3) absence of white-coat hypertension, and (4) standing systolic BP ≥ 110 mmHg without orthostatic symptoms. Risk of decreased organ perfusion by arterial stenosis should be screened before starting intensive BP control. When the target BP differs among comorbidities, the lowest target BP should be given preference. After starting intensive BP lowering therapy, tolerability should be monitored, and the titration should be based on the mean level of blood pressure by office supplemented by out-of-office BPs. Applications of the clinical algorithms will be useful to achieve more standardized and simplified applications of target BP in the elderly.
참고문헌 (61)
- "A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013" (2013)[URL]
- Buckley LF, "Intensive versus standard blood pressure control in SPRINTeligible participants of ACCORD-BP", Diabetes Care, 40, pp.1733~1738 (2017)
- World Health Organization(WHO), "Global health and aging", WHO, ~ (2011)
- Kim KW, "Super aging in South Korea unstoppable but mitigatable : a sub-national scale population projection for best policy planning", Spat Demogr, 8, pp.155~173 (2020)
- 김현창, "Korea hypertension fact sheet 2018", Clinical Hypertension, 25(1), pp.11~14 (2019), 대한고혈압학회[DOI]
- Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- Qaseem A, "Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets : a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians", Ann Intern Med, 166, pp.430~437 (2017)
- Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension, 2018, pp.39, 3021~3104
- Kwang-Il Kim, "2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations", Clinical Hypertension, 25(4), pp.75~88 (2019), 대한고혈압학회[DOI]
- Coca A, "Editorial : hypertension in the elderly", Front Cardiovasc Med, 8, pp.645580~ (2021)
- Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61prospective studies", Lancet, 360, pp.1903~1913 (2002)
- O’Rourke MF, "An updated clinical primer on large artery mechanics : implications of pulse waveform analysis and arterial tonometry", Curr Opin Cardiol, 20, pp.275~281 (2005)
- Ivy A, "Ambulatory blood pressure monitoring to assess the white-coat effect in an elderly East African population", J Clin Hypertens(Greenwich), 17, pp.389~394 (2015)
- Pierdomenico SD, "Prognosis of Masked and white coat uncontrolled hypertension detected by ambulatory blood pressure monitoring in elderly treated hypertensive patients", Am J Hypertens, 30, pp.1106~1111 (2017)
- Spannella F, "Prognostic role of masked and white-coat hypertension : 10-year mortality in treated elderly hypertensives", J Hum Hypertens, 33, pp.741~747 (2019)
- Liguori I, "Orthostatic hypotension in the elderly: a marker of clinical frailty?", J Am Med Dir Assoc, 19, pp.779~785 (2018)
- Zimmermann M, "Orthostatic hypotension as a risk factor for longitudinal deterioration of cognitive function in the elderly", Eur J Neurol, 27, pp.160~167 (2020)
- Szyndler A, "Impact of orthostatic hypotension and antihypertensive drug treatment on total and cardiovascular mortality in a very elderly community-dwelling population", J Hypertens, 37, pp.331~338 (2019)
- Pasina L, "Orthostatic hypotension among elderly patients in Italian internal medicine wards : an observational study", Intern Emerg Med, 15, pp.281~287 (2020)
- Gangavati A, "Hypertension, orthostatic hypotension, and the risk of falls in a communitydwelling elderly population : the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study", J Am Geriatr Soc, 59, pp.383~389 (2011)
- 이주희, "Current status and therapeutic considerations of hypertension in the elderly", The Korean Journal of Internal Medicine, 34(4), pp.687~695 (2019), 대한내과학회[DOI]
- Jylhävä J, , Biol Age Predictors EBioMedicine, 21, pp.29~36 (2017)
- Wu JW, "Biological age in healthy elderly predicts aging-related diseases including dementia", Sci Rep, 11, pp.15929~ (2021)
- Takatori K, "The difference between self-perceived and chronological age in the elderly may correlate with general health, personality and the practice of good health behavior : a cross-sectional study", Arch Gerontol Geriatr, 83, pp.13~19 (2019)
- Yang W, "Effects of antihypertensive drugs on cognitive function in elderly patients with hypertension : a review", Aging Dis, 12, pp.841~851 (2021)
- Zhang W, "Trial of intensive blood-pressure control in older patients with hypertension", N Engl J Med, 385, pp.1268~1279 (2021)
- Yancy CW, "2017ACC", AHA, AHA guideline for the management of heart failure: a report of the American College of Cardiology, pp.American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America, J Am Coll Cardiol[DOI]
- Leung AA, "Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults", Can J Cardiol, 33, pp.557~576 (2017)
- Kleindorfer DO, "2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack : A Guideline From the American Heart Association", American Stroke Association, 2021, pp.52, e364~e467
- PROGRESS Collaborative Group, "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack", Lancet, 358, pp.1033~1041 (2001)
- Anderson TS, "Clinical outcomes after intensifying antihypertensive medication regimens among older adults at hospital discharge", JAMA Intern Med, 179, pp.1528~1536 (2019)
- American Diabetes Association, "10. Cardiovascular disease and risk management: standards of medical care in diabetes: 2021", Diabetes Care, 44(Suppl 1), pp.S125~S150 (2021)
- Kidney Disease, "KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease", Kidney Int, 99, pp.1~87 (2021)
- Potok OA, "The difference between cystatin C-and creatinine-based estimated GFR and associations with frailty and adverse outcomes : a cohort analysis of the Systolic Blood Pressure Intervention Trial(SPRINT)", Am J Kidney Dis, 76, pp.765~774 (2020)
- Beckett NS, "Treatment of hypertension in patients 80 years of age or older", N Engl J Med, 358, pp.1887~1898 (2008)
- Bulpitt CJ, "Does white coat hypertension require treatment over age 80? : Results of the hypertension in the very elderly trial ambulatory blood pressure side project", Hypertension, 61, pp.89~94 (2013)
- SPRINT Research Group, "A randomized trial of intensive versus standard bloodpressure control", N Engl J Med, 373, pp.2103~2116 (2015)
- Juraschek SP, "Orthostatic hypotension, cardiovascular outcomes, and adverse events : results From SPRINT", Hypertension, 75, pp.660~667 (2020)
- Drawz PE, "Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure : results from the SPRINT(Systolic Blood Pressure Intervention Trial)ambulatory blood pressure study", Hypertension, 69, pp.42~50 (2017)
- Sexton DJ, "Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT", JAMA Intern Med, 177, pp.1385~1387 (2017)
- Russo G, "Impact of SPRINT results on hypertension guidelines : implications for"frail"elderly patients", J Hum Hypertens, 32, pp.633~638 (2018)
- Krishnaswami A, "Time to benefit and harm of intensive blood pressure treatment : insights from SPRINT", Eur Heart J Qual Care Clin Outcomes, 7, pp.e1~e2 (2021)
- Basu S, "Benefit and harm of intensive blood pressure treatment : derivation and validation of risk models using data from the SPRINT and ACCORD trials", PLoS Med, 14, pp.e1002410~ (2017)
- Rockwood K, "A global clinical measure of fitness and frailty in elderly people", CMAJ, 173, pp.489~495 (2005)
- Malek Makan A, "Prevalence of preventive cardiovascular medication use in nursing home residents. room for deprescribing? The SHELTER study", J Am Med Dir Assoc, 18, pp.1037~1042 (2017)
- Benetos A, "Hypertension management in older and frail older patients", Circ Res, 124, pp.1045~1060 (2019)
- Benetos A, "An expert opinion from the european society of hypertensioneuropean union geriatric medicine society working group on the management of hypertension in very old, frail subjects", Hypertension, 67, pp.820~825 (2016)
- Williamson JD, "Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years : a randomized clinical trial", JAMA, 315, pp.2673~2682 (2016)
- Bress AP, "Generalizability of SPRINT results to the U.S. adult population", J Am Coll Cardiol, 67, pp.463~472 (2016)
- 정희원, "The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly", The Korean Journal of Internal Medicine, 31(3), pp.594~600 (2016), 대한내과학회
- Studenski S, "Gait speed and survival in older adults", JAMA, 305, pp.50~58 (2011)
- Jinho Shin, "Updated Reasons and Clinical Implications of New Korean Hypertension Guidelines for Cardiologists", Korean Circulation Journal, 50(6), pp.476~484 (2020), 대한심장학회[DOI]
- ), "Am J Cardiol", 2010, 498~503
- Gorelick PB, "Management of blood pressure in stroke", Int J Cardiol Hypertens, 3, pp.100021~ (2019)
- Lanier JB, "Evaluation and management of orthostatic hypotension", Am Fam Physician, 84, pp.527~536 (2011)
- de Havenon AH, "Abstract MP53: intensive blood pressure reduction and secondary stroke risk: a posthoc analysis of the Sps3 trial", Stroke, 52(Suppl_1), pp.AMP53~ (2021)
- Liu J, "Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study", JAMA, 291, pp.2591~2599 (2004)
- Jung KJ, "The ACC", AHA 2013pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic cardiovascular disease, 2015, pp.242, 367~375
- Seo J, "Large discrepancy between unobserved automated office blood pressure and ambulatory blood pressure in a high cardiovascular risk cohort", J Hypertens, 37, pp.42~49 (2019)
- Kojima G, "Prevalence of frailty in nursing homes : a systematic review and meta-analysis", J Am Med Dir Assoc, 16, pp.940~945 (2015)
- Ravindrarajah R, "Systolic blood pressure trajectory, frailty, and all-cause mortality > 80years of age : cohort study using electronic health records", Circulation, 135, pp.2357~2368 (2017)